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Following the publication of our article [1] we noticed an error
in the abstract, within the paragraph headed ‘Results’. The
serine residue, serine-181, referred to in this paragraph
should be serine-180.
The paragraph should therefore read as follows:
Proteins significantly differentially abundant between estro-
gen receptor negative and estrogen receptor positive tumors
at the 0.1% level were consistent with published profiles,
suggesting an altered keratin pool, and increased inflam-
mation and wound responses in estrogen receptor negative
tumors. Two of three spots of PGRMC1 were more abundant
in estrogen receptor negative tumors. Phosphatase treatment
of breast tumor proteins indicated that the PGRMC1
isoforms differed in their phosphorylation status. Simul-
taneous mutation of PGRMC1 serine-56 and serine-180 fully
abrogated the sensitivity of stably transfected MCF7 breast
cancer cells to peroxide-induced cell death. Immune fluores-
cence revealed that PGRMC1 was primarily expressed in ER-
negative basal epithelial cells of mammary ductules. Even in
advanced tumors, high levels of ER or PGRMC1 were almost
mutually exclusive in individual cells. In five out of five
examined ductal in situ breast cancers of comedo type,
PGRMC1 was expressed in glucose transporter 1 negative
or positive poorly oxygenated cells surrounding the necrotic
core, surrounded by a more distal halo of ER-positive cells.
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